EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab By Ogkologos - April 10, 2025 477 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed and refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR New on NCI’s Websites for October 2019 October 3, 2019 Registered Dietitian vs. Nutritionist March 3, 2021 Significant Intracranial Efficacy and Survival Benefits of Osimertinib in Patients with... July 25, 2024 Immunotherapy’s Skin Side Effects: Are Microbes to Blame? July 13, 2022 Load more HOT NEWS Molecular Analysis for Precision Oncology Congress 2024 London, UK, 16-18 October What to Know About Cancer Clinical Trial Matching Programs ESMO Clinical Practice Guideline Express Update on the adoption of physical... Datopotamab Deruxtecan Improves Survival Over Chemotherapy in Patients with Previously Untreated,...
